Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study

Li, Zhen; Fang, Yuan; Chen, Hui; Zhang, Tongchao; Yin, Xiaolin; Man, Jinyu; Yang, Xiaorong; Lü, Ming

doi:10.1016/j.neo.2021.11.013

Cited by 33 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, even though remarkable clinical benefits have been witnessed in the treatments of melanoma, melanoma still poses a great cancer burden globally. The incidence rates of melanoma have increased by 170% from 1990 to 2019, and deaths resulting from it also have increased by 90% worldwide [ 6 ]. A considerable loss of life in years is caused by the cutaneous subtype of melanoma, one of the most common cancers in young adults in their late 20s or early 30s, which calls for the urgent need for a better therapeutic regimen and hopefully, more effective intervention at a much earlier stage in the development of this disease.…”

Section: Introductionmentioning

confidence: 99%

Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies

Yuan

Miao

Mei

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Melanoma is becoming increasingly common worldwide, with high rates of transformation into malignancy compared to other skin lesions. The prognosis of patients with melanoma at an advanced stage is highly unsatisfying despite the development of immunotherapy, target therapy, or combinative therapy. The major barrier to exploiting immune checkpoint therapies and achieving the best benefits clinically is resistance that can easily develop if regimens are not selected appropriately. In this study, we investigated the possibility of using immune-related genes to predict patient survival and their responses to immune checkpoint blocker therapies with the expression profiles available at The Cancer Genome Atlas (TCGA) Program plus expression data from the Gene Expression Omnibus (GEO) for validation. A five gene signature that is highly correlated with the local infiltration of cytotoxic lymphocytes in the tumor microenvironment was identified, and a scoring model was developed with stepwise regression after multivariate Cox analyses. The score calculated strongly correlates with Breslow depth, and this model effectively predicts the prognosis of patients with melanoma, whether primary or metastasized. It also depicts the heterogenous immune-related nature of melanoma by revealing different predicted responses to immune checkpoint blocker therapies through its correlation to tumor immune dysfunction and exclusion (TIDE) score.

show abstract

Section: Introductionmentioning

confidence: 99%

Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies

Yuan

Miao

Mei

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Conversely, if the EAPC estimate and the upper limit of its 95% CI were < 0, the ASR was considered to be trending downward. Otherwise, ASR is considered stable (25)(26)(27)(28)(29). We used the Spearman rank test to explore the influencing factors of EAPC.…”

Section: Statistical Analysesmentioning

confidence: 99%

Spatiotemporal trends of disease burden of edentulism from 1990 to 2019: A global, regional, and national analysis

Man²,

Chen³

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

BackgroundUnderstanding the spatiotemporal trends in disease burden of edentulism is critical to reducing disease burden of edentulism and deploying medical resources. We assessed the changing patterns of disease burden of edentulism at global, regional, and national levels from 1990 to 2019.MethodsData on incident cases, prevalent cases, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) of edentulism were extracted from the Global Burden of Disease 2019 Study. We calculated the estimated annual percentage change (EAPC) to quantify spatiotemporal trends in the ASRs of edentulism.ResultsIn 2019, the number of prevalent cases and DALYs of edentulism were 35.2 and 9.6 million, and the ASPR and ASDR were 43.12/1,000 and 1.18/1,000, with EAPCs of −0.18 [95% confidence interval (CI): −0.28, −0.09] and −0.16[95% CI: −0.26, −0.07] from 1990 to 2019, respectively. Females and the elderly had a higher burden of edentulism. Although the ASPR, ASDR, and ASIR in the high SDI, high–middle SDI, and middle SDI regions showed a decreasing or stable trend, the absolute disease burdens of edentulism in these regions were still high. Although the absolute disease burdens of low SDI and low–middle SDI were low, their ASPR and ASDR showed an upward trend. In countries with high initial disease burden or high SDI, ASPR, ASDR, and ASIR showed stable or declining trends.ConclusionThe absolute disease burden due to edentulism was increasing in many countries and regions. Countries should reduce the disease burden caused by edentulism by adopting measures including the prevention and treatment of dental caries and periodontal disease.

show abstract

“…Even though it only represents 5% of all types of skin neoplasms, CM is considered the most lethal, being responsible for 60-75% of skin cancer-related deaths ( 5 – 7 ). From 1990 to 2019, incident cases of CM have increased by 170% worldwide, faster than most neoplasms, mainly due to a rapidly aging population, changes in lifestyle and better screening ( 8 , 9 ). Furthermore, CM has a higher potential to form metastasis in surrounding tissues than other cancers ( 10 ), which vastly contributes to its lethality and extremely poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness

Cabaço

Tomás²,

Pojo³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Skin cancers are among the most common cancers worldwide and are increasingly prevalent. Cutaneous melanoma (CM) is characterized by the malignant transformation of melanocytes in the epidermis. Although CM shows lower incidence than other skin cancers, it is the most aggressive and responsible for the vast majority of skin cancer-related deaths. Indeed, 75% of patients present with invasive or metastatic tumors, even after surgical excision. In CM, the photoprotective pigment melanin, which is produced by melanocytes, plays a central role in the pathology of the disease. Melanin absorbs ultraviolet radiation and scavenges reactive oxygen/nitrogen species (ROS/RNS) resulting from the radiation exposure. However, the scavenged ROS/RNS modify melanin and lead to the induction of signature DNA damage in CM cells, namely cyclobutane pyrimidine dimers, which are known to promote CM immortalization and carcinogenesis. Despite triggering the malignant transformation of melanocytes and promoting initial tumor growth, the presence of melanin inside CM cells is described to negatively regulate their invasiveness by increasing cell stiffness and reducing elasticity. Emerging evidence also indicates that melanin secreted from CM cells is required for the immunomodulation of tumor microenvironment. Indeed, melanin transforms dermal fibroblasts in cancer-associated fibroblasts, suppresses the immune system and promotes tumor angiogenesis, thus sustaining CM progression and metastasis. Here, we review the current knowledge on the role of melanin secretion in CM aggressiveness and the molecular machinery involved, as well as the impact in tumor microenvironment and immune responses. A better understanding of this role and the molecular players involved could enable the modulation of melanin secretion to become a therapeutic strategy to impair CM invasion and metastasis and, hence, reduce the burden of CM-associated deaths.

show abstract

Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study

Cited by 33 publications

References 46 publications

Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies

Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies

Spatiotemporal trends of disease burden of edentulism from 1990 to 2019: A global, regional, and national analysis

The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness

Contact Info

Product

Resources

About